Physician profile
Jared Nathaniel Smith
NPI 1346865995
$3,119.25
in general payments reported to CMS, 2019-2025
30 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.65 · 2023: $383 · 2024: $1,357 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $566.17 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $422.61 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $352.14 | 2024-2025 | |
| Glaxosmithkline, LLC. | $239.91 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $184.05 | 2023-2025 | |
| Exact Sciences Corporation | $153.88 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $141.88 | 2023-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $113.29 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.87 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $95.13 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.10 | 2023-2025 | Jardiance, Tradjenta |
| Shield Therapeutics INC | $76.13 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $69.25 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $64.30 | 2024-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Verona Pharma, INC. | $59.78 | 2025 | Ohtuvayre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $51.79 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $48.29 | 2024-2025 | Dexcom G6 Transmitter |
| Neurelis, INC. | $35.16 | 2023-2024 | Valtoco |
| Phathom Pharmaceuticals, INC. | $34.05 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $30.25 | 2024 | |
| Ardelyx, INC. | $28.38 | 2024 | Ibsrela |
| Medtronic, INC. | $27.89 | 2024 | Minimed 780g |
| Boston Scientific Corporation | $23.24 | 2024 | Bodyguardian |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.50 | 2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $19.56 | 2023 | |
| Abbott Laboratories | $18.86 | 2024 | Freestyle Libre 3 |
| Janssen Biotech, INC. | $17.75 | 2025 | Tecvayli |
| Sanofi Pasteur INC. | $16.44 | 2022 | |
| Grifols USA, LLC | $13.88 | 2025 | Prolastin-C Liquid |
| Organon LLC | $11.72 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.